NDC 0078-1007

KESIMPTA

Ofatumumab

KESIMPTA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Ofatumumab.

• Product ID: 0078-1007_3d92e626-19d1-4800-8d68-f3380a00787c
• NDC: 0078-1007
• Product Type: Human Prescription Drug
• Proprietary Name: KESIMPTA
• Generic Name: Ofatumumab
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2009-10-26
• Marketing Category: BLA / BLA
• Application Number: BLA125326
• Labeler Name: Novartis Pharmaceuticals Corporation
• Substance Name: OFATUMUMAB
• Active Ingredient Strength: 20 mg/.4mL
• Pharm Classes: CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0078-1007-68

1 SYRINGE, GLASS in 1 CARTON (0078-1007-68) > .4 mL in 1 SYRINGE, GLASS

• Marketing Start Date: 2020-08-20
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "KESIMPTA" or generic name "Ofatumumab"

NDC	Brand Name	Generic Name
0078-1007	KESIMPTA	ofatumumab
0078-0669	ARZERRA	ofatumumab
0078-0690	ARZERRA	ofatumumab